Teruhisa Kato

Toyonaka, 5610825, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Optimization of pyridopyrimidinedione derivatives as non-covalent SARS-CoV-2 3CL protease inhibitors.

Optimization of pyridopyrimidinedione derivatives as non-covalent SARS-CoV-2 3CL protease inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: January 30, 2026

A novel 2-piperazino-pyrimidine compound exhibits asexual antimalarial activity by targeting Plasmodium falciparum plasmepsin X.

A novel 2-piperazino-pyrimidine compound exhibits asexual antimalarial activity by targeting Plasmodium falciparum plasmepsin X.

Journal: International journal for parasitology. Drugs and drug resistance

Published: August 06, 2025

Design, synthesis and biological evaluation of novel quinazolinedione derivatives as non-covalent SARS-CoV-2 3CL protease inhibitors.

Design, synthesis and biological evaluation of novel quinazolinedione derivatives as non-covalent SARS-CoV-2 3CL protease inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: July 19, 2025

Discovery of the Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19.

Discovery of the Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19.

Journal: Journal of medicinal chemistry

Published: July 05, 2025

Accelerating Antimalarial Drug Discovery with a New High-Throughput Screen for Fast-Killing Compounds.

Accelerating Antimalarial Drug Discovery with a New High-Throughput Screen for Fast-Killing Compounds.

Journal: ACS infectious diseases

Published: November 19, 2024

Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission model.

Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission model.

Journal: Antiviral research

Published: August 21, 2024

Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.

Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.

Journal: Antiviral research

Published: November 29, 2023

Peptide-to-Small Molecule: Discovery of Non-Covalent, Active-Site Inhibitors of β-Herpesvirus Proteases.

Peptide-to-Small Molecule: Discovery of Non-Covalent, Active-Site Inhibitors of β-Herpesvirus Proteases.

Journal: ACS medicinal chemistry letters

Published: August 14, 2023

Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model.

Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model.

Journal: Viruses

Published: July 23, 2023

Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.

Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.

Journal: Biochemical and biophysical research communications

Published: December 27, 2022

S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.

S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.

Journal: Science translational medicine

Published: November 03, 2022

Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.

Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.

Journal: The Journal of antimicrobial chemotherapy

Published: October 17, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026